RGEN logo

Repligen Corporation (RGEN)

$131.96

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on RGEN

Market cap

$7.44B

EPS

0.91

P/E ratio

130

Price to sales

8.74

Dividend yield

--

Beta

1.059661

Price on RGEN

Previous close

$137.60

Today's open

$138.13

Day's range

$131.82 - $138.13

52 week range

$100.99 - $175.77

Profile about RGEN

CEO

Olivier Loeillot

Employees

2000

Headquarters

Waltham, MA

Exchange

Nasdaq Global Select

Shares outstanding

56407740

Issue type

Common Stock

RGEN industries and sectors

Healthcare

Biotechnology & Life Sciences

News on RGEN

BioLife Solutions Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of BioLife Solutions, Inc. - BLFS

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of BioLife Solutions, Inc. (NasdaqCM: BLFS) to Repligen Corporation (NasdaqGS: RGEN). Under the terms of the proposed transaction, shareholders of BioLife will receive $11.25 in cash and 0.1442 shares of Repligen common stock for each share of BioLife that they own. KSF is seeking to determine whe.

news source

Business Wire • Jul 24, 2026

news preview

Repligen Corporation (RGEN) M&A Call Transcript

Repligen Corporation (RGEN) M&A Call Transcript

news source

Seeking Alpha • Jul 23, 2026

news preview

BioLife Solutions to be acquired by Repligen in $1.5B cell therapy deal

BioLife Solutions, a Bothell, Wash.-based company developing tools for cell and gene therapy, is being acquired for $1.5 billion by the life sciences corporation Repligen.

news source

GeekWire • Jul 23, 2026

news preview

Repligen to Expand Cell Therapy Capabilities With BioLife Buyout

RGEN's $1.5 billion BioLife acquisition aims to expand its cell therapy capabilities, adding biopreservation products and expected revenue and EPS benefits.

news source

Zacks Investment Research • Jul 23, 2026

news preview

Repligen to buy cell therapy maker BioLife in $1.5 billion deal

Repligen Corp said on ​Wednesday it would buy ‌BioLife Solutions in a cash-and-stock deal valued at about $1.5 ​billion, to expand the drugmaking ​equipment provider's presence in ⁠the fast-growing cell ​therapy market.

news source

Reuters • Jul 22, 2026

news preview

Repligen Strengthens Cell Therapy Portfolio With BioLife Acquisition

Life sciences company Repligen Corporation (NASDAQ:RGEN) on Wednesday agreed to acquire cell processing developer BioLife Solutions Inc. (NASDAQ:BLFS) for an enterprise value of approximately $1.5 billion.

news source

Benzinga • Jul 22, 2026

news preview

Repligen to Buy BioLife Solutions for $1.5 Billion, Expanding Cell Therapy Reach

Repligen NASDAQ: RGEN said it has signed a definitive agreement to acquire BioLife Solutions in a transaction valued at approximately $1.5 billion, adding a cell therapy-focused platform that management said will expand Repligen's exposure to one of the faster-growing areas of bioprocessing.

news source

MarketBeat • Jul 22, 2026

news preview

Repligen to Acquire BioLife Solutions, Expanding Its Cell Therapy Capabilities with Market Leading Biopreservation Media

Fast-tracks Repligen's leadership and customer solution offering in high-growth cell therapy market by adding BioLife's differentiated, high-margin recurring revenue business

news source

GlobeNewsWire • Jul 22, 2026

news preview

Repligen to Report Second Quarter 2026 Financial Results

Webcast and Conference Call to Be Held Tuesday, July 28, 2026, at 8:00 a.m. ET Webcast and Conference Call to Be Held Tuesday, July 28, 2026, at 8:00 a.m. ET

news source

GlobeNewsWire • Jul 15, 2026

news preview

Repligen (RGEN) Down 3.2% Since Last Earnings Report: Can It Rebound?

Repligen (RGEN) reported earnings 30 days ago. What's next for the stock?

news source

Zacks Investment Research • Jun 4, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Repligen Corporation

Open an M1 investment account to buy and sell Repligen Corporation commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in RGEN on M1